Danysz W, Parsons C G, Mobius H J, Stoffler A, Quack G
Department of Pharmacology, Merz+Co., Eckenheimer Landstrasse 100-104, 60318 Frankfurt/Main, FRG.
Neurotox Res. 2000;2(2-3):85-97. doi: 10.1007/BF03033787.
The involvement of glutamate mediated neurotoxicity in the pathogenesis of Alzheimer's disease is finding increasingly more acceptance in the scientific community. Central to this hypothesis is the assumption that in particular glutamate receptors of the N-methyl-D-aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner. Such continuous mild activation leads under chronic conditions to neuronal damage. Moreover, one should consider that impairment of plasticity (learning) may result not only from neuronal damage per se but also from continuous activation of NMDA receptors. To investigate this possibility we tested whether overactivation of NMDA receptors using either non-toxic doses/concentrations of a direct NMDA agonist or through an indirect approach--decrease in magnesium concentration--produces deficits in plasticity. In fact NMDA both in vivo (passive avoidance test) and in vitro (LTP in CA1 region) impaired learning and synaptic plasticity. Under these conditions memantine which is an uncompetitive NMDA receptor antagonist with features of "improved magnesium" (voltage dependence, affinity) attenuated the deficit. The more direct proof that memantine can act as a surrogate for magnesium was obtained in LTP experiments under low magnesium conditions. In this case as well, impaired LTP was restored in the presence of therapeutically relevant concentrations of memantine (1 microM). In vivo, doses leading to similar brain/serum levels produce neuroprotection in animal models relevant for neurodegeneration in Alzheimer's disease such as neurotoxicity produced by inflammation in the NBM or beta-amyloid injection to the hippocampus. Hence, we postulate that if in Alzheimer's disease overactivation of NMDA receptors occurs indeed, memantine would be expected to improve both symptoms (cognition) and slow down disease progression because it takes over the physiological function of magnesium.
谷氨酸介导的神经毒性在阿尔茨海默病发病机制中的作用在科学界越来越被认可。该假说的核心假设是,特别是N-甲基-D-天冬氨酸(NMDA)型谷氨酸受体以持续性而非阵发性方式过度激活。这种持续的轻度激活在慢性条件下会导致神经元损伤。此外,应该考虑到可塑性(学习)受损可能不仅源于神经元损伤本身,还源于NMDA受体的持续激活。为了研究这种可能性,我们测试了使用无毒剂量/浓度的直接NMDA激动剂或通过间接方法——降低镁浓度——使NMDA受体过度激活是否会导致可塑性缺陷。事实上,NMDA在体内(被动回避试验)和体外(CA1区的长时程增强)均损害学习和突触可塑性。在这些条件下,美金刚作为一种具有“改善镁”特性(电压依赖性、亲和力)的非竞争性NMDA受体拮抗剂,减轻了这种缺陷。在低镁条件下的长时程增强实验中获得了更直接的证据,证明美金刚可以作为镁的替代物。在这种情况下,在治疗相关浓度的美金刚(1微摩尔)存在下,受损的长时程增强也得到了恢复。在体内,导致相似脑/血清水平的剂量在与阿尔茨海默病神经退行性变相关的动物模型中产生神经保护作用,如基底前脑炎症或海马注射β-淀粉样蛋白所产生的神经毒性。因此,我们推测,如果在阿尔茨海默病中确实发生了NMDA受体的过度激活,那么美金刚有望改善症状(认知)并减缓疾病进展,因为它承担了镁的生理功能。